| Symbol | MESO |
|---|---|
| Name | MESOBLAST LTD |
| Sector | HEALTH CARE |
| Region | Oceania |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | LEVEL 38, MELBOURNE, VICTORIA, C3 3000 |
| Telephone | 613 9639 6036 |
| Fax | — |
| — | |
| Website | https://www.mesoblast.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001345099 |
| Description | Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Additional info from NASDAQ: |
New Form 3 - MESOBLAST LTD <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001213900-26-048797 <b>Size:</b> 5 KB
Read moreDirector George Gregory 🟢 acquired 8.3M shares of MESOBLAST LTD (MESO) at $14.40 ($26.1M) Transaction Date: Apr 09, 2026 | Filing ID: 008124
Read more